Lymphoma drug trial reports patient deaths despite meeting efficacy endpoint.

A confirmatory trial for ADC Therapeutics' lymphoma drug, Zynlonta, has reported 27 patient deaths, raising significant safety concerns. While the LOTIS-5 trial successfully met its primary endpoint by reducing the risk of death or disease progression, the fatalities could impact the drug's potential for broader second-line utilization. The biotech company plans to discuss these findings with the FDA as it prepares for a full approval submission.